Jean van Wyk, MBChB, MFPM

At IDWeek, Jean van Wyk, MBChB, MFPM, chief medical officer at ViiV Healthcare, discussed the 96-week results from the PASO DOBLE study and the preliminary long-acting injectable PrEP results from the CLARITY study.

At IAS 2025, ViiV’s Jean van Wyk, MBChB, MFPM, shares how real-world data and patient priorities are guiding a new era of HIV care.

At IAS 2025, the VOLITION and OPERA study data show patient preference and real-world use of injectable CAB + RPV LA, informing the treatment strategy of ViiV CMO Jean van Wyk.